RESUMO
The objective of this study was to investigate the mechanism of Toll-like receptor (TLR4)- mediated dendritic cell (DC) immune against Cryptosporidium parvum infection. C. parvum sporozoites were labeled with 5,6-carboxyfluorescein diacetate succinimidyl ester. Murine bone marrow-derived DCs were isolated, and divided into TLR4 antibody blocking (TAB; infected with 2 × 105 labeled sporozoites and 0.5 µg TLR4 blocking antibody), TLR4 antibody unblocking (TAU; infected with 2 × 105 labeled sporozoites), and blank control (BC; with 1.5 mL Roswell Park Memorial Institute 1640 medium) groups. The adhesion of Cryptosporidium sporozoites to DCs and CD11c+ levels were examined by fluorescence microscopy and flow cytometry. Male KM mice were orally injected with C. parvum. The proliferation of T lymphocytes in spleen, expression of cytokines in peripheral blood, and TLR4 distribution features in different organs were further determined by immunohistochemistry. A significantly higher expression of CD11c+ and higher C. parvum sporozoite adhesion were found in the TAU group compared with other groups. The expression of CD4+CD8- /CD8+CD4- in the spleen were obviously differences between the TAB and TAU groups. The expression of TLR4, interleukin IL-4, IL-12, IL-18 and IFN-γ improved in the TAU group compared with TAB group. Higher expression of TLR4 was detected in the lymph nodes of mice in the TAU group, with pathological changes in the small intestine. Hence, TLR4 could mediate DCs to recognize C. parvum, inducing Th1 immune reaction to control C. parvum infection.
Assuntos
Criptosporidiose/imunologia , Células Dendríticas/imunologia , Células Th1/imunologia , Receptor 5 Toll-Like/imunologia , Animais , Cryptosporidium parvum , Citocinas/imunologia , Imunidade Celular , Masculino , CamundongosRESUMO
Objective: To determine the clinical benefits of internal mammary sentinel lymph node biopsy (IM-SLNB) acquired by breast cancer patients with clinically positive axillary lymph node (ALN), and further optimize the IM-SLNB indications. Methods: All primary breast cancer patients with clinically positive ALN from February 2014 to September 2017 were prospectively recruited in this study. IM-SLNB was performed under the guidance of the modified injection technique. The success rate and visualization rate of IM-SLNB, metastatic rate of internal mammary sentinel lymph node (IMSLN) and its related factors were analyzed, and the clinical benefits were accessed according to the current guidelines. Results: Among 126 patients, all of 94 patients (74.6%) who showed internal mammary drainage successfully underwent IM-SLNB. The incidence of internal mammary artery bleeding and pleural lesion were 4.3%(4/94) and 9.6%(9/94), respectively. The metastatic rate of IMSLN was 38.3% (36/94), which was significantly associated with the number of positive ALN (P<0.001) and tumor size (P=0.024). The lymph node staging of 94 patients who underwent IM-SLNB was more accurate. Among them, 36 cases with positive IMSLN underwent internal mammary radiotherapy (IMRT), while the other 58 cases with negative IMSLN avoided radiotherapy. Conclusions: IM-SLNB should be routinely performed in patients with positive ALN. IM-SLNB can provide more accurate staging and guide tailored IMRT to benefit more breast cancer patients.
Assuntos
Neoplasias da Mama/patologia , Biópsia de Linfonodo Sentinela , Axila , Neoplasias da Mama/tratamento farmacológico , Feminino , Humanos , Metástase Linfática , Estadiamento de Neoplasias , Medicina de Precisão , Estudos Prospectivos , Linfonodo Sentinela/patologia , Biópsia de Linfonodo Sentinela/efeitos adversos , Biópsia de Linfonodo Sentinela/estatística & dados numéricosRESUMO
Objective: To evaluate the efficiency of modified Ottawa Ankle Rules (OAR) for the differential diagnosis of fractures in acute foot and ankle injuries. Methods: From October 2016 to December 2016, 272cases (135 males and 137 females) of foot and ankle injury in emergency department of Tianjin Hospital were prospective enrolled in the study.The median age was 27.5 years (7-87); left limb 155, right 117 cases; injury time ranged from 0.3 to 24 h (median 4 h). Conventional and modified OAR was applied on physical examination, subsequently radiography performed to determine the occurrence of fractures.The efficiency of the two methods were compared and analyzed. Results: Fractures were found in 100 cases (36.8%), 49 cases of ankle and 51 cases of foot fractures.With the imaging results as the standard, the sensitivity for conventional and modified OAR were 93.0% and 100%, specificity were 9.9% and 8.7%, the positive predictive value were 37.5% and 38.9%, the negative predictive value were 70.8% and 100%, the accuracy were 40.4% and 42.3%, missed diagnosis rate were 7% and 0% respectively.The sensitivity, positive likelihood ratio, positive predictive value, negative predictive value, accuracy, negative likelihood ratio and missed diagnosis ratio were better than in modified OAR compared with Conventional OAR, while the specificity was slightly lower compared to Conventional OAR.The Kappa value of modified OAR was 0.065 (P>0.05), which is better than conventional OAR.Conventional OAR can reduce 6.3% (17/272) X-ray and modified OAR decline 5.5% (15/272). Conclusion: Modified OAR significantly reduces the rate of missed diagnosis of foot fractures, but its specificity is poor. Ultrasound can be assisted to improve the specificity and reduce the number of unnecessary X-rays.
Assuntos
Traumatismos do Tornozelo , Fraturas Ósseas , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Tornozelo , Criança , Diagnóstico Diferencial , Serviço Hospitalar de Emergência , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Radiografia , Sensibilidade e Especificidade , Adulto JovemRESUMO
Objective: To explore clinical characteristics, treatment, and prognosis of a family with childhood-onset rapid-onset dystonia parkinsonism (RDP) caused by ATP1A3 gene mutation and review literatures. Method: The clinical data of a RDP child, his brother and mother had been analyzed retrospectively. This family was admitted to Xiangya Hospital in January 2016. DNA samples were analyzed by the next-generation sequencing and confirmed by Sanger sequencing. Related literature from PubMed, Online Mendelian Inheritance in Man (OMIM), CNKI and Wanfang databases to date (up to October 2016) with"Rapid-onset dystonia-parkinsonism""RDP""DYT12" as key words was reviewed. Result: The proband boy was three years and four months old (April 2015) when he had the first attack of the disease. After a febricity, he suddenly acquired acute aphasia and limb movement disorder. Rehabilitation therapy and supportive treatment made his speech gradually recovered but still slurred. However, his abnormal walking posture still existed. Nine months later (January 2016, 4 years and one months old), symptoms including aphasia, dysphagia, and weakness with rostrocaudal gradient reoccured after fever. The disease progressed to the critical condition within 24 hours. He"seizured" four times with tonic spasms of limbs but without loss of consciousness. Family history showed his grandparents were consanguineous marriage. His mother and brother also developed abnormal gait and dysarthria after an infection before primary school age. Their symptoms improved gradually without relapsing. However, they did not recover entirely with mild intellectual disability. His mother had a healthy brother and sister. This proband had no other siblings but the brother. Heterozygous missense mutation p. R756H in ATP1A3 gene was detected in this proband, his mother and his brother. This mutation had been reported pathogenically related to RDP, and it located in highly conserved gene region. Benzodiazepine was used for the proband and his brother, with the proband being improved better although not completely. Meanwhile, benzodiazepine had no significant effect on his mother because of poor compliance. This is the first case report of RDP in China. The mutations of ATP1A3 have been previously reported in 51 patients including 6 large families and 16 other unrelated patients. A total of 14 different mutations in ATP1A3 gene with RDP have been reported to date, including 12 missense mutations, a 3-bp in-frame deletion, and a 3-bp in-frame insertion. The sporadic cases all had the typical clinical phenotypes of RDP, such as the abrupt onset of dysarthria, dysphagia, limb dystonia with bradykinesia, and postural instability. The symptoms of bulbar and arms were much more obvious. It was hard to diagnose RDP in a family because some patients had typical symptoms of RDP, while the others might experience from mild symptoms to no symptoms, which might be related to incomplete penetrance of RDP. Two cases carrying the same mutation as our patients also presented some overlapping phenotypes. Conclusion: The p. R756H heterozygous mutation in ATP1A3 gene is the pathogenic mutation of RDP, analysis of genotype-phenotype correlations of RDP will be very important and meaningful.
Assuntos
Distúrbios Distônicos/genética , ATPase Trocadora de Sódio-Potássio/genética , Pré-Escolar , China , Distonia , Extremidades , Feminino , Heterozigoto , Humanos , Masculino , Transtornos dos Movimentos , Mutação , Fenótipo , IrmãosRESUMO
Objective:To investigate the expression of PACAP protein in chronic rhinosinusitis without/with nasal polyps and refractory chronic rhinosinusitis.Method: Fifty-three patients with nasal polyps,70 cases with chronic sinusitis, 28 patients with refractory chronic rhinosinusitis and 20 control cases were enrolled for this study. The expression of PACAP protein was detected by immunochemistry.Result: â PACAP protein were expressed in nasal epitheliumï¼glandular epithelium and goblet cellsï¼â¡The positive intensity of PACAP was" +", " +++", "ï¼-+",and " ++" in nasal polyps, chronic rhinosinusitis, refractory chronic rhinosinusitis, and control group, respectively.Conclusion:PACAP protein mainly locates in nasal epitheliumï¼glandular epithelium and goblet cells. Reduced expression of PACAP may be related with onset of chronic rhiniosinusitis without/with nasal polyps.
RESUMO
BACKGROUND AND AIM: The relationships between dietary nuts and legume intake and risk of stroke are inconsistent. We summarized the evidence by a meta-analysis of prospective cohort studies. METHODS AND RESULTS: We systematically searched the MEDLINE and EMBASE databases up to 31 January 2014. Random-effects models were used to calculate summary relative risks (SRRs) and 95% confidence intervals (CIs). Between-study heterogeneity was assessed using the Cochran's Q and I(2) statistics. Eight prospective studies with a total of 468,887 subjects and 10,493 stroke events were included in the meta-analysis. Overall, a diet containing greater amounts of legumes may be not associated with a lower risk of stroke (SRR = 0.95, 95% CI: 0.84-1.08; P(heterogeneity) = 0.091, I(2) = 43.2%); however, a diet containing greater amounts of nuts may be associated with a lower risk of stroke (SRR = 0.90, 95% CI: 0.81-0.99; P(heterogeneity) = 0.527, I(2) = 0). Gender significantly modified the effects of nut consumption on stroke risk, and high nut intake was associated with reduced risk of stroke in women (SRR = 0.85, 95% CI: 0.75-0.97) other than in men (SRR = 0.95, 95% CI: 0.82-1.11). CONCLUSION: The current meta-analysis provides some evidences for the hypothesis that high intake of dietary nut was inversely associated with stroke risk, whereas dietary legumes intake was not associated with stroke risk.
Assuntos
Fabaceae , Nozes , Acidente Vascular Cerebral/epidemiologia , Estudos de Coortes , Dieta , Feminino , Humanos , Masculino , Estudos Observacionais como Assunto , Risco , Fatores SexuaisRESUMO
OBJECTIVE: In this study, curcumin was designed into the nanoformulation called cubosome with piperine in order to improve oral bioavailability and tissue distribution of curcumin. METHODS: The characteristic of the cubosome was studied by using scanning electron microscope (SEM), Infrared spectrum and small angle X-ray scattering (SAXS) techniques. Tissue distribution of cubosome was measured by liquid chromatography-mass spectrometry (LC-MS) method in mice. RESULTS: The characteristic of the cubosome was demonstrated that the curcumin and piperine were encapsulated in the interior of the cubosome and the crystal form was Pn3m space. The pharmacokinetic test revealed that the cubosome could improve the oral bioavailability significantly compared to the suspension of curcumin with piperine and be mainly absorbed by the spleen. CONCLUSION: These findings provide the reference to a preferable choice of the curcumin formulation and contribute to therapeutic application in clinical research.
Assuntos
Anti-Inflamatórios não Esteroides , Curcumina , Nanocápsulas/química , Alcaloides/química , Alcaloides/farmacocinética , Alcaloides/farmacologia , Animais , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacocinética , Anti-Inflamatórios não Esteroides/farmacologia , Benzodioxóis/química , Benzodioxóis/farmacocinética , Benzodioxóis/farmacologia , Curcumina/química , Curcumina/farmacocinética , Curcumina/farmacologia , Camundongos , Tamanho da Partícula , Piperidinas/química , Piperidinas/farmacocinética , Piperidinas/farmacologia , Alcamidas Poli-Insaturadas/química , Alcamidas Poli-Insaturadas/farmacocinética , Alcamidas Poli-Insaturadas/farmacologia , Espalhamento a Baixo Ângulo , Baço/metabolismo , Técnicas de Cultura de Tecidos , Difração de Raios XRESUMO
Autologous stem cell rescue (ASCT) following high-dose myeloablative chemotherapy is considered to be a therapeutic option for many multiple myeloma (MM) patients; however relapse post ASCT presents a major challenge. The oncolytic potential of reovirus has been previously demonstrated and is currently undergoing phase I monotherapy clinical trials for MM and phase II/III clinical trials for solid tumors. Here we tested the hypothesis that reovirus can successfully purge MM in a murine model that partially recapitulates human MM. RPMI 8226, MM1S, H929 and U266 human myeloma cell lines were exposed to reovirus and oncolysis was assessed. Apheresis product admixed with MM cells was purged with live reovirus (LV) or dead virus (DV) and purging efficacy was monitored via flow cytometry, reverse transcribed-PCR (RT-PCR) and disease relapse in non obese diabetic/severe combined immune deficient (NOD/SCID) mice. Significant LV purging was seen with MM1S, H929 and U266 and the complete ex vivo purging achieved with RPMI 8226 was confirmed by flow cytometry, RT-PCR and absence of disease relapse in vivo. Mice that received LV-purged autografts exhibited 100% survival in comparison to mice that received DV-purged controls. Reovirus's unique ability to kill MM while sparing hematopoietic stem cells places it as an attractive purging agent for MM during ASCT.
Assuntos
Purging da Medula Óssea/métodos , Mieloma Múltiplo/terapia , Terapia Viral Oncolítica , Reoviridae , Animais , Remoção de Componentes Sanguíneos , Linhagem Celular , Linhagem Celular Tumoral , Citometria de Fluxo , Proteínas de Fluorescência Verde/química , Humanos , Masculino , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Recidiva , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Resultado do TratamentoRESUMO
AIM: To understand the role of fengycins in regulating the fumonisin B1 (FB1)production of Fusarium verticillioides. METHODS AND RESULTS: The mass ratio of FB1 to mycelia was determined in order to identify the effect of fengycins on FB1 production. It was shown that the amount of FB1 produced by unit mass mycelia decreased to 28% of the control. Results from mycelia resuspension with fengycins also demonstrated that fengycins had a potent impact on FB1 production. Gene expression patterns using quantitative reverse-transcription PCR (RT-PCR) revealed that the transcriptional levels of both FUM1 and FUM8 (coding enzymes for the generation of FB1) were down-regulated with fengycin treatment. CONCLUSIONS: Fengycins could down-regulate the transcription of some key genes involved in the production of FB1, and impair FB1 synthesis by F. verticillioides. SIGNIFICANCE AND IMPACT OF THE STUDY: These results further improved our understanding of fengycins as the potential candidates to control FB1 contamination in crops and food.
Assuntos
Inibidores Enzimáticos/farmacologia , Fumonisinas/análise , Fumonisinas/metabolismo , Fusarium/efeitos dos fármacos , Fusarium/metabolismo , Lipopeptídeos/farmacologia , Proteínas Fúngicas/biossíntese , Perfilação da Expressão Gênica , Micélio/efeitos dos fármacos , Micélio/metabolismoAssuntos
Estresse Oxidativo , Doença de Parkinson/metabolismo , Animais , Humanos , Modelos Biológicos , Mutação , Doenças Neurodegenerativas/metabolismo , Nitrogênio/metabolismo , Oxigênio/metabolismo , Doença de Parkinson/genética , Complexo de Endopeptidases do Proteassoma/metabolismo , Proteínas/metabolismoRESUMO
A liquid chromatographic-mass spectrometric (LC-MS) assay was developed and validated for the determination of loratadine in human plasma using reversed-phase HPLC combined with electrospray ionization (ESI) mass spectrometry. The analysis involved a simple liquid-liquid extraction. The organic extract was then evaporated and the residue was reconstituted in mobile phase. The reconstituted solution was injected into an HPLC system and was subjected to reverse-phase HPLC on a 5-microm ODS-3 column at a flow-rate of 0.2 ml/min. The mobile phase comprised of acetonitrile-ammonium acetate (pH 4.0; 0.02 M, using formic acid to adjust) using gradient elution. Loratadine was detected in the single ion monitoring (SIM) mode. Standard curves were linear over the concentration range of 0.2-100 ng/ml. The mean predicted concentrations of the quality control (QC) samples deviated by less than 10% from the corresponding nominal values; the intra-assay and inter-assay precision of the assay were within 12% relative standard deviation. The extraction recovery of loratadine was more than 80%. The validated assay was applied to a pharmacokinetic study of loratadine in human plasma following the administration of a single loratadine tablet (40 mg).
Assuntos
Antagonistas dos Receptores Histamínicos H1/sangue , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Loratadina/sangue , Loratadina/farmacocinética , Adolescente , Adulto , Calibragem , Cromatografia Líquida de Alta Pressão , Humanos , Masculino , Padrões de Referência , Reprodutibilidade dos Testes , Soluções , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
Brain and leptomeningeal metastases are common in breast cancer patients and our current treatments are ineffective. Reovirus type 3 is a replication competent, naturally occurring virus that usurps the activated Ras-signaling pathway (or an element thereof) of tumor cells and lyses them but leaves normal cells relatively unaffected. In this study we evaluated reovirus as an experimental therapeutic in models of central nervous system (CNS) metastasis from breast cancer. We found all breast cancer cell lines tested were susceptible to reovirus, with > 50% of these cells lysed within 72 h of infection. In vivo neurotoxicity studies showed only mild local inflammation at the injection site and mild communicating hydrocephalus with neither diffuse encephalitis nor behavioral abnormalities at the therapeutically effective dose of reovirus (intracranial) (ie 10(7) plaque-forming units) or one dose level higher. In vivo, a single intratumoral administration of reovirus significantly reduced the size of tumors established from two human breast cancer cell lines and significantly prolonged survival. Intrathecal administration of reovirus also remarkably prolonged survival in an immunocompetent racine model of leptomeningeal metastases. These data suggest that the evaluation of reovirus as an experimental therapeutic for CNS metastases from breast cancer is warranted.
Assuntos
Neoplasias Encefálicas/secundário , Neoplasias Encefálicas/terapia , Neoplasias da Mama/terapia , Orthoreovirus Mamífero 3 , Infecções por Reoviridae/complicações , Animais , Neoplasias Encefálicas/virologia , Morte Celular , Linhagem Celular Tumoral , Feminino , Proteínas de Fluorescência Verde/genética , Humanos , Injeções Intralesionais , Dose Letal Mediana , Neoplasias Meníngeas/secundário , Neoplasias Meníngeas/terapia , Neoplasias Meníngeas/virologia , Camundongos , Camundongos Nus , Modelos Animais , Neoplasias Experimentais , Transfecção/métodosRESUMO
GNARD (Guangdong Nuclear Accident Real-time Decision support system) is a decision support system for off-site emergency management in the event of an accidental release from the nuclear power plants located in Guangdong province, China. The system is capable of calculating wind field, concentrations of radionuclide in environmental media and radiation doses. It can also estimate the size of the area where protective actions should be taken and provide other information about population distribution and emergency facilities available in the area. Furthermore, the system can simulate and evaluate the effectiveness of countermeasures assumed and calculate averted doses by protective actions. All of the results can be shown and analysed on the platform of a geographical information system (GIS).
Assuntos
Planejamento em Desastres , Reatores Nucleares , Centrais Elétricas , Liberação Nociva de Radioativos , China , Computadores , Bases de Dados como Assunto , Sistemas de Informação Geográfica , Humanos , Sistemas de Informação , SoftwareRESUMO
BACKGROUND: Reovirus is a naturally occurring oncolytic virus that usurps activated Ras-signaling pathways of tumor cells for its replication. Ras pathways are activated in most malignant gliomas via upstream signaling by receptor tyrosine kinases. The purpose of this study was to determine the effectiveness of reovirus as an experimental treatment for malignant gliomas. METHODS: We investigated whether reovirus would infect and lyse human glioma cell lines in vitro. We also tested the effect of injecting live reovirus in vivo on human gliomas grown subcutaneously or orthotopically (i.e., intracerebrally) in mice. Finally, reovirus was tested ex vivo against low-passage cell lines derived from human glioma specimens. All P values were two-sided. RESULTS: Reovirus killed 20 (83%) of 24 established malignant glioma cell lines tested. It caused a dramatic and often complete tumor regression in vivo in two subcutaneous (P =.0002 for both U251N and U87) and in two intracerebral (P =.0004 for U251N and P =.0009 for U87) human malignant glioma mouse models. As expected, serious toxic effects were found in these severely immunocompromised hosts. In a less immunocompromised mouse model, a single intratumoral inoculation of live reovirus led to a dramatic prolongation of survival (compared with control mice treated with dead virus; log-rank test, P<.0001 for both U251N and U87 cell lines). The animals treated with live virus also appeared to be healthier and gained body weight (P =.0001). We then tested the ability of reovirus to infect and kill primary cultures of brain tumors removed from patients and found that it killed nine (100%) of nine glioma specimens but none of the cultured meningiomas. CONCLUSIONS: Reovirus has potent activity against human malignant gliomas in vitro, in vivo, and ex vivo. Oncolysis with reovirus may be a potentially useful treatment for a broad range of human cancers.
Assuntos
Neoplasias Encefálicas/terapia , Glioma/terapia , Orthoreovirus Mamífero 3/fisiologia , Animais , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/virologia , Feminino , Glioma/patologia , Glioma/virologia , Humanos , Masculino , Orthoreovirus Mamífero 3/isolamento & purificação , Camundongos , Camundongos Endogâmicos NOD , Camundongos Nus , Camundongos SCID , Taxa de Sobrevida , Transplante Heterólogo , Células Tumorais CultivadasRESUMO
This study was conducted to investigate effects of leaves of mulberry tree (Morus alba) as a protein supplement to isonitrogenously replace rapeseed meal (RSM) on performance of growing lambs offered ammoniated rice straw (ABRS) (Trial 1), and to evaluate the digestive characteristics of the ABRS supplemented with different ratios of RSM and mulberry leaves in terms of in vitro gas production (Trial 2). In Trial 1, 45 Huzhou lambs were divided into five equal groups according to their body weight and gender. Lambs in each group were kept in three pens (male, female and mixed (one male and two females)), and received one of the following dietary treatments: 100g RSM (A), 75g RSM plus 60g mulberry leaves (B), 50g RSM plus 120g mulberry leaves (C), 25g RSM plus 180g mulberry leaves (D), and 240g mulberry leaves (E). All animals were given ABRS ad libitum along with 100g ground corn per head per day. The intake of ABRS was slightly increased with the supplementary level of mulberry leaves, and hence total intake increased with the increasing level of mulberry leaves. The growth rates were higher in diets A and E than those in other treatments (P<0.05), with little difference between diets A and E, and the slowest in C. Animals of all genders showed a similar trend, though male lambs was higher in weight gain than the female. While feed efficiency was higher in diet A, concentrate consumption per kilogram of weight gain was lower when higher level of mulberry leaves was supplemented (diets D and E). Feed cost per kilogram gain was lower in diets E and A compared to other treatments. Degradation of dry matter in the rumen of sheep were higher for mulberry leaves than for RSM, but crude protein was less degraded for mulberry leaves than for RSM. The potential GP was significantly higher in diet A than those in B, C and D (P<0.05), and higher in E than in C (P<0.05) (Trial 2), indicating a negative associate effect of mulberry leaves and RSM on digestion. It is inferred that mulberry leaves may be used as a protein supplement to ammoniated straw diets to fully substitute for RSM, but these two supplements should unlikely be supplemented together to avoid the negative associate effect.
RESUMO
At supraphysiological levels, IGF-I bypasses some forms of insulin resistance and has been proposed as a therapeutic agent in the treatment of diabetes. Unfortunately, side effects of high-dose IGF-I (100-250 microg/kg) have precluded its clinical use. Low-dose IGF-I (40-80 microg/kg), however, shows minimal side effects but has not been systematically evaluated. In our previous study under conditions of declining glucose, low-dose IGF-I infusion was more effective in stimulating glucose utilization, but less effective in suppressing glucose production and lipolysis than low-dose insulin. However, under conditions of hyperglycemia, we could not observe any differential effects between high-dose infusions of IGF-I and insulin. To determine whether the differential effects of IGF-I and insulin are dose-related or related to the prevailing glucose level, 3 h glucose clamps were performed in the same animal model as in the previous studies, i.e. the moderately hyperglycemic (175 mg/dl) insulin-infused depancreatized dog, with additional infusions of low-dose IGF-I (67.8 microg/kg, i.e. 29.1 microg/kg bolus plus 0.215 microg/kg( )per min infusion; n=5) or insulin 49.5 mU/kg (9 mU/kg bolus plus 0.45 mU/kg per min; n=7). As in the previous study under conditions of declining glucose, low-dose IGF-I had significant metabolic effects in vivo, in our model of complete absence of endogenous insulin secretion. Glucose production was similarly suppressed with both IGF-I and insulin, by 54+/-3 and 56+/-2% s.e. (P=NS) respectively. Glucose utilization was stimulated to the same extent (IGF-I 5.2+/-0.2, insulin 5.5+/-0.3 mg/kg per min, P=NS). Glucagon, free fatty acid, glycerol, alanine and beta-hydroxybutyrate, were suppressed, while lactate and pyruvate levels were raised, similarly with IGF-I and insulin. We conclude that: (i) differential effects of IGF-I and insulin may be masked under hyperglycemic conditions, independent of the hormone dose; (ii) low-dose IGF-I has no selective advantage over additional insulin in suppressing glucose production and lipolysis, nor in stimulating glucose utilization during hyperglycemia and subbasal insulin infusion when insulin secretion is absent, as in type 1 diabetes mellitus.
Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Fator de Crescimento Insulin-Like I/administração & dosagem , Insulina/uso terapêutico , Ácido 3-Hidroxibutírico/sangue , Alanina/sangue , Análise de Variância , Animais , Cães , Esquema de Medicação , Ácidos Graxos não Esterificados/sangue , Técnica Clamp de Glucose , Glicerol/sangue , Fator de Crescimento Insulin-Like I/uso terapêutico , Ácido Láctico/sangue , Masculino , Pancreatectomia , Ácido Pirúvico/sangueRESUMO
In addition to suppressing appetite, leptin may also modulate insulin secretion and action. Leptin was administered here to insulin-resistant rats to determine its effects on secretagogue-stimulated insulin release, whole body glucose disposal, and insulin-stimulated skeletal muscle glucose uptake and transport. Male Wistar rats were fed either a normal (Con) or a high-fat (HF) diet for 3 or 6 mo. HF rats were then treated with either vehicle (HF), leptin (HF-Lep, 10 mg. kg(-1). day(-1) sc), or food restriction (HF-FR) for 12-15 days. Glucose tolerance and skeletal muscle glucose uptake and transport were significantly impaired in HF compared with Con. Whole body glucose tolerance and rates of insulin-stimulated skeletal muscle glucose uptake and transport in HF-Lep were similar to those of Con and greater than those of HF and HF-FR. The insulin secretory response to either glucose or tolbutamide (a pancreatic beta-cell secretagogue) was not significantly diminished in HF-Lep. Total and plasma membrane skeletal muscle GLUT-4 protein concentrations were similar in Con and HF-Lep and greater than those in HF and HF-FR. The findings suggest that chronic leptin administration reversed a high-fat diet-induced insulin-resistant state, without compromising insulin secretion.
Assuntos
Gorduras na Dieta/farmacologia , Resistência à Insulina/fisiologia , Leptina/farmacologia , Proteínas Musculares , Músculo Esquelético/metabolismo , 3-O-Metilglucose/farmacocinética , Animais , Glicemia/metabolismo , Índice de Massa Corporal , Dieta , Ingestão de Energia/fisiologia , Técnica Clamp de Glucose , Teste de Tolerância a Glucose , Transportador de Glucose Tipo 4 , Glicogênio/metabolismo , Hiperinsulinismo/metabolismo , Hipoglicemiantes/farmacologia , Insulina/sangue , Masculino , Proteínas de Transporte de Monossacarídeos/metabolismo , Músculo Esquelético/efeitos dos fármacos , Ratos , Ratos Wistar , Tolbutamida/farmacologiaRESUMO
We examined a possible mechanistic interaction between leptin and thyroid hormones in rats with hypothyroidism induced by thyroidectomy (TX) and propylthiouracil administration. In study 1, the TX rats were treated by vehicle (V, n = 9) or by recombinant murine leptin (L, 0.3 mg. kg(-1). day(-1), n = 9) or were pair-fed (PF, n = 9) against L. In study 2, the TX rats were all given 3, 3'5'-triiodo-L-thyronine (T(3)) replacement (T, 5 microg. kg(-1). day(-1)) to correct hypothyroidism. They were then subdivided into three groups, namely, vehicle (T+V, n = 9), leptin (T+L, n = 10), and pair-feeding (T+PF, n = 9), similar to study 1 except for T(3) (T). Reduced food consumption and weight gain in the TX rats were reversed by T(3) replacement. Leptin suppressed food intake in the TX rats regardless of T(3) replacement. O(2) consumption (VO(2)) and CO(2) production (VCO(2)) were reduced in TX rats (P < 0.05 vs. normal) but were normalized by either T(3) or leptin treatment. T+L additively increased VO(2) and VCO(2) (P < 0.05 vs. TX, T(3), and L). The respiratory exchange ratio was unaltered in TX rats, with and without T(3), but was significantly reduced by L or T+L treatments. These results indicate that the metabolic actions of leptin are not dependent on a normal thyroid status and that the effects of leptin and T(3) on oxidative metabolism are additive.
Assuntos
Metabolismo Energético/efeitos dos fármacos , Hipotireoidismo/metabolismo , Leptina/farmacologia , Tri-Iodotironina/farmacologia , Animais , Peso Corporal/efeitos dos fármacos , Peso Corporal/fisiologia , Calorimetria Indireta , Respiração Celular/efeitos dos fármacos , Respiração Celular/fisiologia , Interações Medicamentosas , Ingestão de Alimentos/efeitos dos fármacos , Ingestão de Alimentos/fisiologia , Metabolismo Energético/fisiologia , Hipotireoidismo/tratamento farmacológico , Masculino , Consumo de Oxigênio/efeitos dos fármacos , Consumo de Oxigênio/fisiologia , Ratos , Ratos Sprague-Dawley , TireoidectomiaRESUMO
Leptin (OB protein) elicits a neuroendocrine response to starvation and states of nutritional abundance to stabilize the proportion of body fat. Leptin has dramatic effects on food intake and energy expenditure in adult and juvenile rodents. However, whether the neonatal period is associated with the development of an effective leptin feedback system is still not known. In this study, we evaluated the effects of peripherally administered leptin on body weight changes in neonatal rats during the early suckling period (from birth to 10 d). Our results show that daily i.p. injections of leptin (0.3 microg/g and 1.0 microg/g) to neonatal rats led to a significant reduction in weight gain over 10 d compared with the control group (p < 0.01 and p < 0.01, respectively). Concomitant with a reduction in weight gain, retroperitoneal fat pad weight also significantly decreased in the leptin-treated group. Our data indicate that the potential for energy balance regulation by leptin occurs in the first day after birth. In addition, we also observed that 3 d after discontinuing leptin treatment, the body weight as well as the fat pad weight of leptin-treated pups returned to the control level. Our results demonstrate that leptin reduces body weight gain in neonatal rats.
Assuntos
Peso Corporal/efeitos dos fármacos , Leptina/administração & dosagem , Animais , Animais Recém-Nascidos , Alterações do Peso Corporal , Injeções Intraperitoneais , Ratos , Ratos Sprague-DawleyRESUMO
The study aim was to investigate the effect of the route of insulin treatment on the glucagon and glucose production (GP) responses to hypoglycemia in the diabetic rat. Experiments were performed in 4 groups of rats: (1) streptozotocin (STZ)-induced diabetic, untreated (D, n = 7), (2) diabetic treated with subcutaneous insulin (DSC, n = 8), (3) diabetic treated with intraperitoneal insulin (DIP, n = 6), and (4) normal control (N, n = 10). Slow-release insulin implants were used in DSC and DIP rats for 10 to 14 days (3 U/d). A hyperinsulinemic (120 pmol x kg(-1) x min(-1) insulin)-hypoglycemic (glycemia = 2.5 +/- 0.1 mmol/L) clamp following an isoglycemic basal period was performed in 5-hour fasted rats. Basal plasma glucose was normalized in both DSC and DIP rats; however, in DSC but not DIP rats, glucose normalization required peripheral hyperinsulinemia. Tracer-determined GP, which was elevated in D rats, was completely normalized in DIP but only partially corrected in DSC rats. Basal glucagon levels were similar in all groups. During hypoglycemia, GP was suppressed in D rats (delta, -28.9 +/- 5.0 micromol x kg(-1) x min(-1), moderately increased in DSC rats (delta, 6.1 +/- 5.6, P < .01 v D), but markedly increased in DIP and N rats (delta, 34.5 +/- 4.5 for DIP and 16.8 +/- 2.8 for N; P < .01 vD, P < .05 for DIP v DSC or N). Plasma glucagon increased 6-fold in N (945 +/- 129 pg/mL), only doubled in D (424 +/- 54), and tripled in DSC (588 +/- 83), but increased 5-fold in DIP rats (1,031 +/- 75, P < .05 v D and DSC). We conclude that in STZ-diabetic rats, (1) intraperitoneal but not subcutaneous insulin treatment normalizes basal GP, and (2) intraperitoneal insulin treatment as compared with subcutaneous treatment alleviates peripheral hyperinsulinemia and results in increased glucagon and GP responses to hypoglycemia.